Role of CYP2C19 alleles in the management of recurrent ischemic stroke

CYP2C19 is the primary enzyme involved in the activation of clopidogrel, an antiplatelet agent used for secondary stroke prevention. An individual's alleles are used to understand their -clopidogrel metabolizer phenotype. Single nucleotide polymorphisms of the gene result in altered metabolism...

Full description

Saved in:
Bibliographic Details
Published in:Neurology. Clinical practice 2019-04, Vol.9 (2), p.140-144
Main Authors: Lyerly, Michael J, Bartlett, Kelly, Albright, Karen C
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CYP2C19 is the primary enzyme involved in the activation of clopidogrel, an antiplatelet agent used for secondary stroke prevention. An individual's alleles are used to understand their -clopidogrel metabolizer phenotype. Single nucleotide polymorphisms of the gene result in altered metabolism of this prodrug. Three ischemic stroke cases were treated with clopidogrel. Despite confirming adequate drug exposure, medication adherence, and ruling out drug-drug interactions, all had recurrent ischemic stroke. Each case had a *2/*17 genotype, categorizing them as intermediate clopidogrel metabolizers. Even with the gain-of-function allele, the loss-of-function allele resulted in lack of prodrug activation, leading to decreased efficacy in platelet inhibition. These cases illustrate the importance of a thoughtful approach to secondary stroke prevention and demonstrate the utility of pharmacogenomic testing in clopidogrel hyporesponders. Recognition of the importance of genotyping has the potential to enable better selection of appropriate secondary prevention strategies.
ISSN:2163-0402
2163-0933
DOI:10.1212/CPJ.0000000000000584